New FDA-Approved Indication for Crizotinib Capsules

The U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for crizotinib (Xalkori^®, Pfizer) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic leukemia kinase-positive. 

Read the Full Prescribing Information.

Read the Press Release.

Posted 1/26/2021